Laverty joins Eisai
Prior to joining Novartis, Laverty worked in several corporate policy, corporate affairs, and product public affairs positions at Bristol-Myers Squibb Company.
A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.
US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...